Literature DB >> 12217766

Parafallopian tube transitional cell carcinoma.

Gladell P Paner1, Miguel Gonzalez, Hytham Al-Masri, Donna Marie Smith, Aliya N Husain.   

Abstract

BACKGROUND: Transitional cell carcinoma (TCC) has recently been acknowledged as a distinct histologic pattern of the uncommon primary fallopian tube carcinoma. However, rare cases of TCC that are closely associated to the extraluminal portion of the tube remain widely unrecognized. CASE: We present a left adnexal high-grade TCC in a 56-year-old postmenopausal woman with an elevated serum CA-125 level. The tumor was attached by a small stalk to the serosal surface of the left fallopian tube and was completely separate from the uninvolved uterus and ipsilateral ovary. Histologic examination of the tubal lumen epithelium revealed neither atypia nor involvement by the neoplasm. Immunohistochemistry showed the tumor cells to be positive for pankeratin, calretinin, progesterone and estrogen receptors, and cytokeratin 7, and negative for cytokeratin 20, consistent with a Mullerian derivation.
CONCLUSION: Our case represents the fourth reported instance of a primary paratubal TCC. Perhaps, this entity falls under a previously unrecognized category of carcinomas that collectively may arise from Walthard's rest, paratubal cyst, or directly from the tubal serosa.

Entities:  

Mesh:

Year:  2002        PMID: 12217766     DOI: 10.1006/gyno.2002.6777

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Primary transitional cell carcinoma of the fallopian tube in a premenopausal woman: A case report and review of literature.

Authors:  Manoj R Babu; Altaf Gauhar Haji; K Chitrathara; D K Vijaykumar; Jayeeta Samanta; K R Hiran
Journal:  Indian J Med Paediatr Oncol       Date:  2009-01

2.  Prevalence of endosalpingiosis and other benign gynecologic lesions.

Authors:  Jan Sunde; Morgan Wasickanin; Tiffany A Katz; Emily L Wickersham; D O Emilie Steed; Novae Simper
Journal:  PLoS One       Date:  2020-05-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.